Pfizer COVID-19 shots are 91% valid with updated data, protected from South African variants

The Pfizer and BioNTech COVID-19 vaccines are about 91% effective in preventing the disease, they said Thursday, citing the latest test data, including participants who were indirectly inoculated for up to 6 months.

This shot was also 100% effective in preventing illness in South African study participants. In South Africa, the number of participants was relatively small at 800, but a new variant called B1351 prevailed.

The new overall efficacy rate of 91.3% is lower than the 95% initially reported in the 44,000 trial in November, but since then many variants have become widespread worldwide.

Pfizer CEO Albert Bourla said the latest results, including data on more than 12,000 people who were fully vaccinated for at least six months, help pharmaceutical companies get full regulatory approval from the United States. He said he was in a position to submit.

The vaccine is currently approved by the US Food and Drug Administration in an emergency.

In a statement, BioNTech CEO U─čur Shahin said, “The vaccine provides the first clinical results that can effectively protect against circulating mutants. This reaches herd immunity. And it’s an important factor in ending this pandemic. “

Experts fear that new variants of COVID-19 from South Africa and Brazil may be resistant to existing vaccines and treatments. According to federal data, more than 300 cases of South African variants have been detected in more than 25 US states and jurisdictions.

Vaccines are 100% effective in preventing severe illness, as defined by the US Centers for Disease Control and Prevention, and 95.3% effective in preventing severe illness, as defined by the US Food and Drug Administration. It was a target.

The two companies also said that there were no significant safety concerns among study participants from the second dose to 6 months later.

They added that they are generally equally effective, regardless of age, race, gender, ethnicity, and even among participants with a variety of existing medical conditions.

“These data support our view that we have a really strong vaccine,” said Danny Altmann, a professor of immunology at Imperial College London in the United Kingdom who was not involved in the Pfizer trial. I did.

He showed that the vaccine is likely to provide effective protection in a real-world environment where several different coronavirus variants may be circulating, so its effectiveness against South African variants is “It’s especially noteworthy,” he said.

The study examined more than 900 confirmed cases of COVID-19, most of them among participants who received placebo.

The release of the updated results follows another data showing that the vaccine is safe and effective at ages 12-15, in the United States and Europe for pharmaceutical companies to use shots of this age group. It’s been paving the way for approval for weeks.

Karl O’Donnell